Fernando Gonzalez, MD

Title(s)Associate Professor, Pediatrics
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown University, Providence, RISc.B.1997Neuroscience
    Brown University, Providence, RIM.D.2001School of Medicine
    Harbor-UCLA Medical Center, Torrance, CA2004Pediatrics
    UCSF, San Francisco, CA2007Neonatal-Perinatal Medicine

    Collapse Overview 
    Collapse Overview
    My research is focused on determining how the full-term brain responds to acute injury during the neonatal period, and strategies to enhance neuroplasticity and long-term functional outcomes. My specific research goals are to: (1) clearly define the neuronal subpopulations that are vulnerable to ischemia and critical for neurodevelopment, (2) determine the mechanisms of injury and endogenous repair in the immature brain, and (3) define therapeutic strategies to enhance long-term function. Specifically, I am interested in how the immature brain differs from the adult brain in its response to stroke, and how reparative mechanisms can be enhanced with delayed therapy. Throughout my training, I have had broad exposure to various aspects of central nervous system (CNS) development and repair, including: evaluation and inhibition of pain through direct CNS treatment; the effects of local injury on wound healing and phagocytosis; direct evaluation of behavioral, cognitive, and nociceptive function after injury; pathophysiologic mechanisms of early brain injury; and the effects of exogenous therapy on early brain injury. Of these experiences, the ones I found most compelling were those that linked rigorous basic science at the bench to investigation of human disease. For example, my research on the short-term effects of exogenous erythropoietin treatment on neurogenesis after early rodent stroke prompted a study to determine beneficial treatment strategies that improve long-term functional outcomes. This project showed that prolonged erythropoietin treatment is most effective for long-term behavioral improvement, a finding that informed clinical studies in humans to treat neonatal brain injury. My current research is focused on cell type-specific changes in the peri-infarct cortex, including alterations in cell fate, function, and circuit formation. This will have a significant impact in improving knowledge and identifying novel therapies to treat early injury. It is my clear desire to apply this type of translational approach to the field of neonatal brain injury, thereby unifying my interest in neuroscience and brain development with a goal of improving the care of the newborn.

    Collapse Research 
    Collapse Research Activities and Funding
    Quantifying Metabolic Changes in the Newborn Brain Following Stroke
    NIH/NCATS RAS A127522Jun 1, 2018 - May 31, 2019
    Role: PI
    Enhanced cellular therapy for neonatal stroke
    NIH/NINDS R01NS107039Dec 15, 2017 - Nov 30, 2021
    Role: Principal Investigator
    Role Description: The goal of this project is to determine the mechanisms of regeneration and repair with delayed cellular therapy for neonatal stroke by focusing on the vascular response to brain injury. This will study the effects of mesenchymal stem cells pre-treated with erythropoietin on long-term outcomes.
    Cerebral focal ischemia-reperfusion injury
    Anida Pharma, Inc. AnidaMar 1, 2017 - Feb 28, 2018
    Role: Co-investigator
    Precision Therapy for Neonatal Brain Injury
    NIH/NINDS R35NS097299Dec 1, 2016 - Nov 30, 2024
    Role: Co-Investigator
    High-dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) CCC
    NIH/NINDS U01NS092764Sep 30, 2016 - Jun 30, 2021
    Role: Site-PI, Executive Committee Member
    The Role of Erythropoietin in Enhancing Synaptic Plasticity and Neural Circuit Formation after Neonatal Stroke
    UCSF REACJan 1, 2015 - Jun 30, 2016
    Role: PI
    Repair after Neonatal Brain Injury
    NIH/NINDS P01NS082330Jan 1, 2014 - Dec 31, 2018
    Role: Co-Investigator
    Harrington DiscoveryJan 1, 2014 - Dec 31, 2015
    Role: Co-Investigator
    Effects of neonatal stroke and erythropoietin on cell fate and neurogenesis
    UCSF RAPJan 1, 2012 - Dec 31, 2014
    Role: PI
    Erythropoietin and Neurogenesis after Neonatal Stroke
    NIH/NINDS K08NS064094Mar 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    Mechanisms of Ischemic Neonatal Brain Injury
    NIH/NINDS P50NS035902Apr 1, 1997 - Jan 31, 2014
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wu YW, Goodman AM, Chang T, Mulkey SB, Gonzalez FF, Mayock DE, Juul SE, Mathur AM, Van Meurs K, McKinstry RC, Redline RW. Placental pathology and neonatal brain MRI in a randomized trial of erythropoietin for hypoxic-ischemic encephalopathy. Pediatr Res. 2019 Jul 01. PMID: 31261373.
      View in: PubMed
    2. Soul JS, Pressler R, Allen M, Boylan G, Rabe H, Portman R, Hardy P, Zohar S, Romero K, Tseng B, Bhatt-Mehta V, Hahn C, Denne S, Auvin S, Vinks A, Lantos J, Marlow N, Davis JM. Recommendations for the design of therapeutic trials for neonatal seizures. Pediatr Res. 2019 Jun; 85(7):943-954. PMID: 30584262.
      View in: PubMed
    3. Cornet MC, Pasupuleti A, Fang A, Gonzalez F, Shimotake T, Ferriero DM, Glass HC, Cilio MR. Predictive value of early EEG for seizures in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. Pediatr Res. 2018 09; 84(3):399-402. PMID: 29895836.
      View in: PubMed
    4. Juul SE, Comstock BA, Heagerty PJ, Mayock DE, Goodman AM, Hauge S, Gonzalez F, Wu YW. High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol. Neonatology. 2018; 113(4):331-338. PMID: 29514165.
      View in: PubMed
    5. Larpthaveesarp A, Gonzalez FF. Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats. J Vis Exp. 2017 04 21; (122). PMID: 28518065.
      View in: PubMed
    6. Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, Van Meurs KP, Rogers EE, Gonzalez FF, Comstock BA, Juul SE, Msall ME, Bonifacio SL, Glass HC, Massaro AN, Dong L, Tan KW, Heagerty PJ, Ballard RA. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial. Pediatrics. 2016 06; 137(6). PMID: 27244862.
      View in: PubMed
    7. Larpthaveesarp A, Georgevits M, Ferriero DM, Gonzalez FF. Delayed erythropoietin therapy improves histological and behavioral outcomes after transient neonatal stroke. Neurobiol Dis. 2016 09; 93:57-63. PMID: 27142685.
      View in: PubMed
    8. Larpthaveesarp A, Ferriero DM, Gonzalez FF. Growth factors for the treatment of ischemic brain injury (growth factor treatment). Brain Sci. 2015 Apr 30; 5(2):165-77. PMID: 25942688; PMCID: PMC4493462.
    9. Wu YW, Gonzalez FF. Erythropoietin: a novel therapy for hypoxic-ischaemic encephalopathy? Dev Med Child Neurol. 2015 Apr; 57 Suppl 3:34-9. PMID: 25800490.
      View in: PubMed
    10. van Velthoven CT, Gonzalez F, Vexler ZS, Ferriero DM. Stem cells for neonatal stroke- the future is here. Front Cell Neurosci. 2014; 8:207. PMID: 25120432; PMCID: PMC4110439.
    11. Gonzalez FF, Larpthaveesarp A, McQuillen P, Derugin N, Wendland M, Spadafora R, Ferriero DM. Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke. 2013 Mar; 44(3):753-8. PMID: 23391775; PMCID: PMC3689426.
    12. Xiong T, Gonzalez F, Mu DZ. An overview of risk factors for poor neurodevelopmental outcome associated with prematurity. World J Pediatr. 2012 Nov; 8(4):293-300. PMID: 23151855.
      View in: PubMed
    13. Fang AY, Gonzalez FF, Sheldon RA, Ferriero DM. Effects of combination therapy using hypothermia and erythropoietin in a rat model of neonatal hypoxia-ischemia. Pediatr Res. 2013 Jan; 73(1):12-7. PMID: 23085817; PMCID: PMC3540182.
    14. Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang T, Durand DJ, Song D, Bonifacio SL, Gonzalez FF, Glass HC, Juul SE. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012 Oct; 130(4):683-91. PMID: 23008465; PMCID: PMC3457622.
    15. Gonzalez FF, Fang A, Ferriero DM. Is erythropoietin the answer? Pediatr Res. 2011 Jan; 69(1):2-3. PMID: 21150548.
      View in: PubMed
    16. Wang H, Tang J, Xiong Y, Li X, Gonzalez F, Mu D. Neonatal community-acquired pneumonia: pathogens and treatment. J Paediatr Child Health. 2010 Nov; 46(11):668-72. PMID: 20796185.
      View in: PubMed
    17. Spadafora R, Gonzalez FF, Derugin N, Wendland M, Ferriero D, McQuillen P. Altered fate of subventricular zone progenitor cells and reduced neurogenesis following neonatal stroke. Dev Neurosci. 2010 Jul; 32(2):101-13. PMID: 20453463.
      View in: PubMed
    18. Gonzalez FF, Ferriero DM. Neuroprotection in the newborn infant. Clin Perinatol. 2009 Dec; 36(4):859-80, vii. PMID: 19944839; PMCID: PMC2786822.
    19. Gonzalez FF, Abel R, Almli CR, Mu D, Wendland M, Ferriero DM. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci. 2009; 31(5):403-11. PMID: 19672069; PMCID: PMC2820334.
    20. Gonzalez FF, Ferriero DM. Therapeutics for neonatal brain injury. Pharmacol Ther. 2008 Oct; 120(1):43-53. PMID: 18718848.
      View in: PubMed
    21. Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, Ferriero DM. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci. 2007; 29(4-5):321-30. PMID: 17762200.
      View in: PubMed
    22. Gonzalez FF, Miller SP. Does perinatal asphyxia impair cognitive function without cerebral palsy? Arch Dis Child Fetal Neonatal Ed. 2006 Nov; 91(6):F454-9. PMID: 17056843; PMCID: PMC2672766.
    23. Guo TZ, Reid K, Davies MF, Nacif-Coelho C, Rabin BC, Gonzalez F, Maze M. Chronic desipramine treatment desensitizes the rat to anesthetic and antinociceptive effects of the alpha2-adrenergic agonist dexmedetomidine. Anesthesiology. 1998 Jun; 88(6):1634-42. PMID: 9637658.
      View in: PubMed